Orforglipron, a daily GLP-1 receptor agonist pill, lowered HbA1c by up to 1.6% and body weight by 7.9% in a phase III trial ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

ATLANTA, April 11, 2025 /PRNewswire/ -- On April 01, 2025, OrderlyMeds received a Cease-and-Desist letter from Eli Lilly regarding the compounding of Tirzepatide. This is our open response.

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Thursday, shares of Eli Lilly (Symbol: LLY) entered into oversold territory, hitting an RSI reading of 29.5 ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares closed yesterday at $726.24.

One of them is the pharmaceutical industry. However, some major executives in the sector are not optimistic, including Eli Lilly's (NYSE: LLY) CEO, David Ricks. Start Your Mornings Smarter!

INDIANAPOLIS — Eli Lilly and Company says it's suing an Indianapolis-based weight loss clinic that it claims is misleading patients about drugs being sold. Lilly claims Premier Weight Loss is selling ...

On Tuesday, Goldman Sachs upgraded shares of Eli Lilly (NYSE:LLY) from Neutral to Buy, while slightly reducing the price target to $888 from $892. The firm's analyst highlighted the pharmaceutical ...

The bottom line: After taking the opportunity to reassess the relative merits of the pipelines of the two firms, we’re raising our fair value estimate for Lilly to $650 per share from $620 and ...

Eli Lilly and Sangamo Therapeutics have entered into a licensing agreement worth over $1.4bn to deliver genomic medicines for central nervous system (CNS) diseases. The deal gives Lilly an exclusive ...

In contrast, Goldman upgraded Eli Lilly to Buy from Neutral, maintaining a price target of $888. It sees Lilly as “the sector’s premier topline grower,” driven by leadership in the obesity ...